New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
06:31 EDTXLRNAcceleron Pharma price target raised to $65 from $35 at Piper Jaffray
Piper Jaffray raised its price target for Acceleron Pharma shares to $65 ahead of the clinical data read-outs it expects to start in June. Piper expects share value to be driven by the company's clinical progress for dalantercept, as it sees blockbuster potential in multiple cancers. The firm reiterates an Overweight rating on Acceleron.
News For XLRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
07:21 EDTXLRNUBS to hold a conference
Subscribe for More Information
May 18, 2015
07:31 EDTXLRNCelgene, Acceleron granted fast track designations for luspatercept
Subscribe for More Information
May 15, 2015
08:51 EDTXLRNAcceleron management to meet with Leerink
Subscribe for More Information
May 13, 2015
17:40 EDTXLRNAcceleron to present DART study data at ASCO
Acceleron Pharma, a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, announced that data from the DART study, an ongoing phase 2 clinical trial of dalantercept in patients with advanced renal cell carcinoma will be presented at the 2015 American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago, Illinois.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use